

**Germline *CARD11* mutation in a patient with severe congenital B cell lymphocytosis.**

Andrew S. Brohl<sup>a\*</sup>, Jeffrey Stinson<sup>b\*</sup>, Helen C. Su<sup>c</sup>, Thomas Badgett<sup>d</sup>, Chester D. Jennings<sup>e</sup>, Gauthaman Sukumar<sup>f</sup>, Sivasish Sindiri<sup>a</sup>, Wei Wang<sup>g</sup>, Lela Kardava<sup>g</sup>, Susan Moir<sup>g</sup>, Clifton L. Dalgard<sup>f</sup>, Jeffrey A. Moscow<sup>d#</sup>, Andrew L. Snow<sup>b#§</sup>, & Javed Khan<sup>a#§</sup>.

<sup>a</sup>Oncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

<sup>b</sup>Department of Pharmacology, Uniformed Services University of Health Sciences, Bethesda, MD

<sup>c</sup>Laboratory of Host Defenses, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD

<sup>d</sup>Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, KY

<sup>e</sup>Department of Pathology, College of Medicine, University of Kentucky, Lexington, KY

<sup>f</sup>Department of Anatomy, Physiology & Genetics, Uniformed Services University of Health Sciences, Bethesda, MD

<sup>g</sup>Immunopathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD


\*Authors contributed equally

#Authors contributed equally



§Corresponding Authors

Andrew L. Snow, Ph.D.  
Dept of Pharmacology, C2013  
Uniformed Services University of the Health Sciences  
4301 Jones Bridge Rd.  
Bethesda, MD 20814  
301-295-3267  
[andrew.snow@usuhs.edu](mailto:andrew.snow@usuhs.edu)


Javed Khan, M.D.  
Oncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health  
37 Convent Drive,  
Building 37, Room 2016B  
Bethesda, Maryland 20892301-435-2937  
[khanjav@mail.nih.gov](mailto:khanjav@mail.nih.gov)



**Supplemental Figure 1. Predominant B cell lymphocytosis in patient's lymph node.** Resected lymph node tissue from the patient was immunohistochemically stained with anti-CD20 to mark B cells. White arrow indicates a distinct B cell follicle. Power = 100X.

**A****B**

**Supplemental Figure 2. Comparable activation status of control and patient B cells following stimulation.** (A) Flow cytometric comparison of cell size and shape (forward vs. side scatter) for purified naïve B cells activated for 5 days using the stimuli listed at top. (B) Upregulation of B cell activation markers (CD86, CD25, CD83) was assessed by flow cytometry following 3 days of activation with the stimuli listed at top. Data are representative of three independent experiments.



**Supplemental Figure 3. Hierarchical clustering analysis of gene expression in naïve B cells from controls and BENTA patients.** Transcriptome expression data (FPKM) was log<sub>2</sub> transformed and standardized. Unsupervised clustering was performed using Ward's minimum variance agglomeration method. The height is weighted squared distance between cluster centers.